Pulling SEC filings + quote and writing the call…
RLMD
RELMADA THERAPEUTICS, INC.
Next earnings Aug 5, 2026 · consensus $-0.19 EPS
Last earnings +1.2% on 2026-05-12
$6.81
▲ +1.11%$6.73▲ +850.43%
over 1Y
L $0.54EODHDH $7.86
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today+1.1%
1W+3.2%
1M-4.3%
3M+7.7%
YTD+54.0%
1Y+850.4%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 11 analysts
Buy
Conservative balance sheet (liabilities/equity 0.09x); but revenue fell -35.4% YoY.
RELMADA THERAPEUTICS, INC. shows $5.13K in FY2013 revenue (-35.4% YoY), a -1118837.3% net margin, and -66.3% ROE.
Sources: SEC EDGAR (CIK 0001553643, latest 10-Q filed 2026-05-12) · EODHD · as of 6/22/2026, 1:53:16 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.